Indisulam (BioDeep_00000180008)

 

Secondary id: BioDeep_00000015347

human metabolite blood metabolite


代谢物信息卡片


N-(3-Chloro-1H-indol-7-yl)-4-sulphamoylbenzenesulphonamide

化学式: C14H12ClN3O4S2 (384.9958)
中文名称: N-(3-氯-1H-吲哚-7-基)-1,4-苯二磺酰胺
谱图信息: 最多检出来源 Homo sapiens(blood) 99.22%

分子结构信息

SMILES: C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
InChI: InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)

描述信息

C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor
D004791 - Enzyme Inhibitors > D002257 - Carbonic Anhydrase Inhibitors
C471 - Enzyme Inhibitor > C29577 - Carbonic Anhydrase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
D000970 - Antineoplastic Agents

同义名列表

11 个代谢物同义名

N-(3-Chloro-1H-indol-7-yl)-4-sulphamoylbenzenesulphonamide; N-(3-Chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide; N(1)-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulphonamide; N(1)-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; N-(3-Chloro-7-indolyl)-1,4-benzenedisulphonamide; N-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide; Indisulamum; Indisulam; e-7070; e7070



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Jiaqi Lu, Dan Li, Honglv Jiang, Yue Li, Chengpaio Lu, Tao Chen, Yuhong Wang, Xiaohui Wang, Wenzhao Sun, Zhongjian Pu, Chunhua Qiao, Jingjing Ma, Guoqiang Xu. The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1. The Journal of biological chemistry. 2023 Feb; ?(?):103025. doi: 10.1016/j.jbc.2023.103025. [PMID: 36805336]
  • Jiaqi Lu, Honglv Jiang, Dan Li, Tao Chen, Yuhong Wang, Zhongjian Pu, Guoqiang Xu. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells. Journal of proteome research. 2021 09; 20(9):4462-4474. doi: 10.1021/acs.jproteome.1c00437. [PMID: 34420308]
  • Xinglong Jia, Lulu Pan, Mingrui Zhu, Hao Hu, Linhui Zhai, Jie Liu, Min Hu, Bin Liu, Minjia Tan. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate. Journal of proteomics. 2020 01; 210(?):103545. doi: 10.1016/j.jprot.2019.103545. [PMID: 31626998]
  • Hacer Cesur, Israel Rubinstein, Ashwini Pai, Hayat Onyüksel. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine : nanotechnology, biology, and medicine. 2009 Jun; 5(2):178-83. doi: 10.1016/j.nano.2008.09.001. [PMID: 19071064]
  • Mika Hilvo, Anna Maria Salzano, Alessio Innocenti, Markku S Kulomaa, Andrea Scozzafava, Andrea Scaloni, Seppo Parkkila, Claudiu T Supuran. Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. Journal of medicinal chemistry. 2009 Feb; 52(3):646-54. doi: 10.1021/jm801267c. [PMID: 19193158]
  • W S Siegel-Lakhai, A S Zandvliet, A D R Huitema, M M Tibben, G Milano, V Girre, V Diéras, A King, E Richmond, J Wanders, J H Beijnen, J H M Schellens. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. British journal of cancer. 2008 Apr; 98(8):1320-6. doi: 10.1038/sj.bjc.6604300. [PMID: 18414469]
  • Anthe S Zandvliet, Jan H M Schellens, William Copalu, Jos H Beijnen, Alwin D R Huitema. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. Journal of pharmacokinetics and pharmacodynamics. 2006 Oct; 33(5):543-70. doi: 10.1007/s10928-006-9021-5. [PMID: 16946998]
  • Anthe S Zandvliet, William Copalu, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug metabolism and disposition: the biological fate of chemicals. 2006 Jun; 34(6):1041-6. doi: 10.1124/dmd.105.008326. [PMID: 16565173]
  • Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Atsushi Horiike, Yasuhito Fujisaka, Kyoko Takayama, Terumi Sakamoto, Yuki Nishioka, Sanae Yasuda, Tomohide Tamura. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer science. 2005 Oct; 96(10):721-8. doi: 10.1111/j.1349-7006.2005.00109.x. [PMID: 16232205]
  • Jan-Hendrik Beumer, Michel J X Hillebrand, Dick Pluim, Hilde Rosing, Karen Foley, S Murray Yule, Jan H M Schellens, Jos H Beijnen. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Investigational new drugs. 2005 Aug; 23(4):317-30. doi: 10.1007/s10637-005-1440-4. [PMID: 16012791]
  • Alessandro Cecchi, Alzbeta Hulikova, Jaromír Pastorek, Silvia Pastoreková, Andrea Scozzafava, Jean-Yves Winum, Jean-Louis Montero, Claudiu T Supuran. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. Journal of medicinal chemistry. 2005 Jul; 48(15):4834-41. doi: 10.1021/jm0501073. [PMID: 16033263]
  • Charlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, Ron A A Mathôt, Cornelis J A Punt, Jean-Pierre Armand, Eric Raymond, Alwin D R Huitema, Christian Dittrich, Herlinde Dumez, Henri H Roché, Jean-Pierre Droz, Miroslav Ravic, S Murray Yule, Jantien Wanders, Jos H Beijnen, Pierre Fumoleau, Jan H M Schellens. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investigational new drugs. 2005 Jun; 23(3):225-34. doi: 10.1007/s10637-005-6730-3. [PMID: 15868378]
  • H J G Desirée van den Bongard, Rolf W Sparidans, David J P Critchley, Jos H Beijnen, Jan H M Schellens. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Investigational new drugs. 2004 Apr; 22(2):151-8. doi: 10.1023/b:drug.0000011791.75522.de. [PMID: 14739663]
  • Jan Hendrik Beumer, Hilde Rosing, Michel J X Hillebrand, Lianda G A H Nan-Offeringa, Karen Foley, S Murray Yule, Albert J R Heck, Jan H M Schellens, Jos H Beijnen. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2004; 18(23):2839-48. doi: 10.1002/rcm.1699. [PMID: 15517526]
  • H J G D van den Bongard, D Pluim, R C A M van Waardenburg, M Ravic, J H Beijnen, J H M Schellens. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anti-cancer drugs. 2003 Jul; 14(6):405-10. doi: 10.1097/00001813-200307000-00003. [PMID: 12853880]
  • C Terret, S Zanetta, H Roché, J H M Schellens, M N Faber, J Wanders, M Ravic, J P Droz. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). European journal of cancer (Oxford, England : 1990). 2003 May; 39(8):1097-104. doi: 10.1016/s0959-8049(03)00128-x. [PMID: 12736109]
  • Charlotte van Kesteren, R A A Mathôt, E Raymond, J P Armand, P Fumoleau, C Punt, M Ravic, J Wanders, J H Beijnen, J H M Schellens. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). British journal of clinical pharmacology. 2002 Nov; 54(5):463-71. doi: 10.1046/j.1365-2125.2002.01684.x. [PMID: 12445024]
  • Ch Van Kesteren, R A A Mathôt, E Raymond, J P Armand, Ch Dittrich, H Dumez, H Roché, J P Droz, C Punt, M Ravic, J Wanders, J H Beijnen, P Fumoleau, J H M Schellens. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Oct; 20(19):4065-73. doi: 10.1200/jco.2002.01.005. [PMID: 12351604]
  • H J G Desirée van sen Bongard, Dick Pluim, Hilde Rosing, Lianda Nan-Offeringa, Margaret Schot, Miroslav Ravic, Jan H M Schellens, Jos H Beijnen. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anti-cancer drugs. 2002 Sep; 13(8):807-14. doi: 10.1097/00001813-200209000-00004. [PMID: 12394264]